Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Receiver Tank Dell practices with Texans less than a month after being wounded in shooting
Police Minister admits NZ cannot compete with Australian recruitment offer
US defense chief denies genocide committed in Gaza
Pope skips Good Friday procession 'to preserve his health'
Hometown of Laura Ingalls Wilder set for a growth spurt
Pair arrested for alleged theft of $20,000 worth of Lego
How to make sure your leftovers are safe to eat
Biden hosts Kishida in official visit as US, Japan bolster defense ties
At least 6 Egyptian women die after vehicle slides off ferry and plunges into Nile River
Dealing with fast spreading pest hits new milestone for Otago Regional Council
Mississippi woman pleads guilty to stealing government funds
Media Minister had 'more than enough time' to find solutions